Mammalian Cell Fermentation Technology Market Report, 2032

Mammalian Cell Fermentation Technology Market - By Type (Chinese Hamster Ovary (CHO), Human Embryonic Kidney (HEK)), Application (Monoclonal Antibodies, Recombinant Proteins), End-use (Biopharmaceutical Companies, CMOs & CDMOs) & Forecast, 2023-2032

Report Content

Chapter 1&nbsp;&nbsp;&nbsp;Methodology &amp; Scope

1.1&nbsp;&nbsp;&nbsp; Market definition

1.2&nbsp;&nbsp;&nbsp; Base estimates &amp; calculations

1.3&nbsp;&nbsp;&nbsp; Forecast parameters

1.4&nbsp;&nbsp;&nbsp; COVID-19 impact analysis at global level

1.5&nbsp;&nbsp;&nbsp; Data validation

1.6&nbsp;&nbsp;&nbsp; Data sources

1.6.1&nbsp;&nbsp;&nbsp; Primary

1.6.2&nbsp;&nbsp;&nbsp; Secondary

1.6.2.1&nbsp;&nbsp;&nbsp;Paid sources

1.6.2.2&nbsp;&nbsp;&nbsp;Public sources

Chapter 2&nbsp;&nbsp;&nbsp;Executive Summary

2.1&nbsp;&nbsp;&nbsp; Global mammalian cell fermentation technology industry 360&ordm; synopsis, 2018 &ndash; 2032

2.1.1&nbsp;&nbsp;&nbsp; Business trends

2.1.2&nbsp;&nbsp;&nbsp; Regional trends

2.1.3&nbsp;&nbsp;&nbsp; Type trends

2.1.4&nbsp;&nbsp;&nbsp; Application trends

2.1.5&nbsp;&nbsp;&nbsp; End-use trends

Chapter 3&nbsp;&nbsp;&nbsp;Mammalian Cell Fermentation Technology Industry Insights

3.1&nbsp;&nbsp;&nbsp; Industry landscape

3.2&nbsp;&nbsp;&nbsp; Industry impact forces

3.2.1&nbsp;&nbsp;&nbsp; Growth drivers

3.2.1.1&nbsp;&nbsp;&nbsp;Increasing demand for biologics

3.2.1.2&nbsp;&nbsp;&nbsp;Increasing investment in research and development of novel recombinant proteins

3.2.1.3&nbsp;&nbsp;&nbsp;Increasing focus on personalized medicine and precision medicine

3.2.2&nbsp;&nbsp;&nbsp; Industry pitfalls &amp; challenges

3.2.2.1&nbsp;&nbsp;&nbsp;High cost associated with the production of biologics using mammalian cell fermentation technology

3.2.2.2&nbsp;&nbsp;&nbsp;Regulatory challenges

3.3&nbsp;&nbsp;&nbsp; Growth potential analysis

3.3.1&nbsp;&nbsp;&nbsp; By type

3.3.2&nbsp;&nbsp;&nbsp; By application

3.3.3&nbsp;&nbsp;&nbsp; By end-use

3.4&nbsp;&nbsp;&nbsp; COVID- 19 impact analysis

3.5&nbsp;&nbsp;&nbsp; Regulatory landscape

3.5.1&nbsp;&nbsp;&nbsp; U.S.

3.5.2&nbsp;&nbsp;&nbsp; Europe

3.6&nbsp;&nbsp;&nbsp; Technology landscape

3.7&nbsp;&nbsp;&nbsp; Porter&#39;s analysis

3.8&nbsp;&nbsp;&nbsp; PESTEL analysis

Chapter 4&nbsp;&nbsp;&nbsp;Competitive Landscape, 2022

4.1&nbsp;&nbsp;&nbsp; Introduction

4.2&nbsp;&nbsp;&nbsp; Company matrix analysis, 2022

4.3&nbsp;&nbsp;&nbsp; Competitive analysis of major market players

4.4&nbsp;&nbsp;&nbsp; Company positioning matrix

4.5&nbsp;&nbsp;&nbsp; Strategy dashboard, 2022

Chapter 5&nbsp;&nbsp;&nbsp;Mammalian Cell Fermentation Technology Market, By Type, 2018 - 2032 (USD Million)

5.1&nbsp;&nbsp;&nbsp; Key trends, by type

5.2&nbsp;&nbsp;&nbsp; Chinese Hamster Ovary (CHO) cell fermentation

5.3&nbsp;&nbsp;&nbsp; Human Embryonic Kidney (HEK) cell fermentation

5.4&nbsp;&nbsp;&nbsp; Baby Hamster Kidney (BHK) cell fermentation

5.5&nbsp;&nbsp;&nbsp; Murine myeloma cell fermentation

5.6&nbsp;&nbsp;&nbsp; Other types

Chapter 6&nbsp;&nbsp;&nbsp;Mammalian Cell Fermentation Technology Market, By Application, 2018 &ndash; 2032 (USD Million)

6.1&nbsp;&nbsp;&nbsp; Key trends, by application

6.2&nbsp;&nbsp;&nbsp; Monoclonal antibodies

6.3&nbsp;&nbsp;&nbsp; Recombinant proteins

6.4&nbsp;&nbsp;&nbsp; Vaccines

6.5&nbsp;&nbsp;&nbsp; Hormones

6.6&nbsp;&nbsp;&nbsp; Enzymes

6.7&nbsp;&nbsp;&nbsp; Other applications

Chapter 7&nbsp;&nbsp;&nbsp;Mammalian Cell Fermentation Technology Market, By End-use, 2018 &ndash; 2032 (USD Million)

7.1&nbsp;&nbsp;&nbsp; Key trends, by end-use

7.2&nbsp;&nbsp;&nbsp; Biopharmaceutical Companies

7.3&nbsp;&nbsp;&nbsp; CMOs &amp; CDMOs

7.4&nbsp;&nbsp;&nbsp; Academic &amp; Research Institutes

Chapter 8&nbsp;&nbsp;&nbsp;Mammalian Cell Fermentation Technology Market, By Region, 2018 &ndash; 2032 (USD Million)

8.1&nbsp;&nbsp;&nbsp; Key trends, by region

8.2&nbsp;&nbsp;&nbsp; North America

8.2.1&nbsp;&nbsp;&nbsp; U.S.

8.2.2&nbsp;&nbsp;&nbsp; Canada

8.3&nbsp;&nbsp;&nbsp; Europe

8.3.1&nbsp;&nbsp;&nbsp; Germany

8.3.2&nbsp;&nbsp;&nbsp; UK

8.3.3&nbsp;&nbsp;&nbsp; France

8.3.4&nbsp;&nbsp;&nbsp; Spain

8.3.5&nbsp;&nbsp;&nbsp; Italy

8.3.6&nbsp;&nbsp;&nbsp; Rest of Europe

8.4&nbsp;&nbsp;&nbsp; Asia Pacific

8.4.1&nbsp;&nbsp;&nbsp; Japan

8.4.2&nbsp;&nbsp;&nbsp; China

8.4.3&nbsp;&nbsp;&nbsp; India

8.4.4&nbsp;&nbsp;&nbsp; Australia

8.4.5&nbsp;&nbsp;&nbsp; Rest of Asia Pacific

8.5&nbsp;&nbsp;&nbsp; Latin America

8.5.1&nbsp;&nbsp;&nbsp; Brazil

8.5.2&nbsp;&nbsp;&nbsp; Mexico

8.5.3&nbsp;&nbsp;&nbsp; Rest of Latin America

8.6&nbsp;&nbsp;&nbsp; MEA

8.6.1&nbsp;&nbsp;&nbsp; South Africa

8.6.2&nbsp;&nbsp;&nbsp; Saudi Arabia

8.6.3&nbsp;&nbsp;&nbsp; Rest of MEA

Chapter 9&nbsp;&nbsp;&nbsp;Company Profiles

9.1&nbsp;&nbsp;&nbsp; Thermo Fisher Scientific, Inc.

9.2&nbsp;&nbsp;&nbsp; Merck KGaA

9.3&nbsp;&nbsp;&nbsp; Danaher Corporation

9.4&nbsp;&nbsp;&nbsp; Lonza Group Ltd

9.5&nbsp;&nbsp;&nbsp; F. Hoffmann-La Roche Ltd

9.6&nbsp;&nbsp;&nbsp; Sartorius AG

9.7&nbsp;&nbsp;&nbsp; AstraZeneca PLC

9.8&nbsp;&nbsp;&nbsp; Bristol-Myers Squibb Company

9.9&nbsp;&nbsp;&nbsp; Amgen Inc.

9.10&nbsp;&nbsp;&nbsp; Gilead Sciences, Inc.

9.11&nbsp;&nbsp;&nbsp; Moderna, Inc.

9.12&nbsp;&nbsp;&nbsp; Regeneron Pharmaceuticals, Inc. 
&nbsp;

Mammalian Cell Fermentation Technology Market

Get a free sample of this report